Skip to content

Bilateral Sacroiliac Joint (SIJ) Injection in Lumbar Disc Prolapse

Therapeutic Potentials of Bilateral Sacroiliac Joint Injection in Lumbar Disc Prolapse: a Prospective Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04326699
Enrollment
86
Registered
2020-03-30
Start date
2020-03-15
Completion date
2020-10-15
Last updated
2020-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain, Mechanical, Lumbar Disc Herniation, Sciatica, Spine Stiffness

Keywords

Disc Prolapse, sacroiliac joint, Injection, Ultrasound

Brief summary

Bilateral sacroiliac joint injection in symptomatic lumbar disc prolapse under ultrasound guidance and studying the effect of this technique on pain, spine mobility and activity of daily living.

Detailed description

86 Patients with lumbar disc prolapse diagnosed by either MRI or CT will be included. All of them aged \> 18 years with no special condition for the duration of disc prolapse. All of them had clinical manifestations in the form of mechanical low back pain or sciatica or limited spine mobility. All participants had no or poor response to conservative treatment. Previous surgery, severe facet arthropathy, ankylosing spondylitis, sensory or motor deficit and wedge fracture were considered as exclusion criteria. Distraction, compression, thigh thrust, and sacral thrust were used to assess SIJ dysfunction only at baseline before injection. Fingertip to floor and Oswestry disability index (ODI) were used to assess mobility and function of the spine at baseline (before and after injection) and after 2 and 16 weeks. Visual Analogue Scale (VAS) was used for pain appraisal at the same intervals. Participants will be randomly assigned into active and control group using 1:1 allocation. In the active group bilateral SIJ injection will be performed under ultrasound US guidance. Under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ.

Interventions

PROCEDUREBilateral SIJ injection

under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Lumbar disc prolapse diagnosed by either MRI or CT were included. * All of them aged \> 18 years * No special condition for the duration of disc prolapse. * All of them had clinical manifestations in the form of mechanical low back pain or sciatica or limited spine mobility. * All participants had no or poor response to conservative treatment

Exclusion criteria

* Previous surgery * Severe facet arthropathy * Ankylosing spondylitis * Sensory or motor deficit * Wedge fracture

Design outcomes

Primary

MeasureTime frameDescription
Pain assessment by visual analogue scale.at baseline 0 time, after 2 weeks and after 16 weeksVisual analogue scale, 0 means no pain and 10 means the maximum possible pain.
Spine mobility, finger tip to floor testBaseline 0 time, after 2 weeks and after 16 weekscomparison to the intial values with each visit to detect changes with no definite references.
Oswestry disability indexBaseline 0 time, after 2 weeks and after 16 weeks0 value means no disability and 100 means complete disability

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026